EP1532272A2 - Immunmarker zur diagnostik und therapie im zusammenhang mit transplantat-reaktionen - Google Patents
Immunmarker zur diagnostik und therapie im zusammenhang mit transplantat-reaktionenInfo
- Publication number
- EP1532272A2 EP1532272A2 EP03750429A EP03750429A EP1532272A2 EP 1532272 A2 EP1532272 A2 EP 1532272A2 EP 03750429 A EP03750429 A EP 03750429A EP 03750429 A EP03750429 A EP 03750429A EP 1532272 A2 EP1532272 A2 EP 1532272A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- nucleic acid
- acid molecule
- rejection
- nucleotide sequence
- tolerance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000006243 chemical reaction Methods 0.000 title claims abstract description 57
- 238000002560 therapeutic procedure Methods 0.000 title description 30
- 238000003745 diagnosis Methods 0.000 title description 7
- 238000000034 method Methods 0.000 claims abstract description 50
- 238000011321 prophylaxis Methods 0.000 claims abstract description 7
- 238000011282 treatment Methods 0.000 claims abstract description 7
- 206010061218 Inflammation Diseases 0.000 claims abstract description 5
- 230000004054 inflammatory process Effects 0.000 claims abstract description 5
- 238000003759 clinical diagnosis Methods 0.000 claims abstract 2
- 238000011281 clinical therapy Methods 0.000 claims abstract 2
- 108020004707 nucleic acids Proteins 0.000 claims description 99
- 102000039446 nucleic acids Human genes 0.000 claims description 99
- 150000007523 nucleic acids Chemical class 0.000 claims description 99
- 239000002773 nucleotide Substances 0.000 claims description 55
- 125000003729 nucleotide group Chemical group 0.000 claims description 55
- 230000014509 gene expression Effects 0.000 claims description 41
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 27
- 210000004027 cell Anatomy 0.000 claims description 24
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 22
- 230000008569 process Effects 0.000 claims description 20
- 210000003734 kidney Anatomy 0.000 claims description 19
- 238000001514 detection method Methods 0.000 claims description 16
- 229920001184 polypeptide Polymers 0.000 claims description 16
- 239000013598 vector Substances 0.000 claims description 15
- 108020004999 messenger RNA Proteins 0.000 claims description 14
- 210000002216 heart Anatomy 0.000 claims description 13
- 210000001519 tissue Anatomy 0.000 claims description 13
- 108020004635 Complementary DNA Proteins 0.000 claims description 12
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 12
- 230000000694 effects Effects 0.000 claims description 12
- 239000002299 complementary DNA Substances 0.000 claims description 10
- 230000001965 increasing effect Effects 0.000 claims description 9
- 230000001404 mediated effect Effects 0.000 claims description 9
- 238000007792 addition Methods 0.000 claims description 7
- 238000012217 deletion Methods 0.000 claims description 7
- 230000037430 deletion Effects 0.000 claims description 7
- 230000002068 genetic effect Effects 0.000 claims description 7
- 238000003780 insertion Methods 0.000 claims description 7
- 230000037431 insertion Effects 0.000 claims description 7
- 238000006467 substitution reaction Methods 0.000 claims description 7
- 230000005945 translocation Effects 0.000 claims description 7
- 229960005486 vaccine Drugs 0.000 claims description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 6
- 210000004185 liver Anatomy 0.000 claims description 6
- 108020004414 DNA Proteins 0.000 claims description 5
- 230000000692 anti-sense effect Effects 0.000 claims description 4
- 230000001717 pathogenic effect Effects 0.000 claims description 4
- 230000001575 pathological effect Effects 0.000 claims description 4
- 208000023275 Autoimmune disease Diseases 0.000 claims description 3
- 208000024869 Goodpasture syndrome Diseases 0.000 claims description 3
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 claims description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 3
- 230000009368 gene silencing by RNA Effects 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 210000000952 spleen Anatomy 0.000 claims description 3
- 208000026872 Addison Disease Diseases 0.000 claims description 2
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims description 2
- 208000023345 Autoimmune Diseases of the Nervous System Diseases 0.000 claims description 2
- 208000031212 Autoimmune polyendocrinopathy Diseases 0.000 claims description 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 2
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 2
- 206010028372 Muscular weakness Diseases 0.000 claims description 2
- 206010034277 Pemphigoid Diseases 0.000 claims description 2
- 108010029485 Protein Isoforms Proteins 0.000 claims description 2
- 102000001708 Protein Isoforms Human genes 0.000 claims description 2
- 206010037549 Purpura Diseases 0.000 claims description 2
- 206010042742 Sympathetic ophthalmia Diseases 0.000 claims description 2
- 210000000709 aorta Anatomy 0.000 claims description 2
- 230000001363 autoimmune Effects 0.000 claims description 2
- 208000000594 bullous pemphigoid Diseases 0.000 claims description 2
- 210000000845 cartilage Anatomy 0.000 claims description 2
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims description 2
- 230000000052 comparative effect Effects 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 201000008350 membranous glomerulonephritis Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 230000036473 myasthenia Effects 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- 230000003582 thrombocytopenic effect Effects 0.000 claims description 2
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 claims description 2
- 206010012468 Dermatitis herpetiformis Diseases 0.000 claims 1
- 208000032843 Hemorrhage Diseases 0.000 claims 1
- 210000002469 basement membrane Anatomy 0.000 claims 1
- 210000000056 organ Anatomy 0.000 abstract description 28
- 238000012544 monitoring process Methods 0.000 abstract description 5
- 230000008105 immune reaction Effects 0.000 abstract description 3
- 239000012634 fragment Substances 0.000 description 25
- 241001465754 Metazoa Species 0.000 description 23
- 238000001574 biopsy Methods 0.000 description 20
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 20
- 230000006870 function Effects 0.000 description 18
- 239000000126 substance Substances 0.000 description 15
- 238000002054 transplantation Methods 0.000 description 15
- 230000001154 acute effect Effects 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 230000001684 chronic effect Effects 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 229940109239 creatinine Drugs 0.000 description 10
- 230000001939 inductive effect Effects 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 210000002700 urine Anatomy 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 230000006866 deterioration Effects 0.000 description 9
- 230000008595 infiltration Effects 0.000 description 9
- 238000001764 infiltration Methods 0.000 description 9
- 241000282414 Homo sapiens Species 0.000 description 8
- 230000001506 immunosuppresive effect Effects 0.000 description 7
- 210000005087 mononuclear cell Anatomy 0.000 description 7
- 238000010171 animal model Methods 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 5
- 239000003018 immunosuppressive agent Substances 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 230000004217 heart function Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000005923 long-lasting effect Effects 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- 101150087675 RIB5 gene Proteins 0.000 description 3
- 206010052779 Transplant rejections Diseases 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000011443 conventional therapy Methods 0.000 description 3
- 238000003748 differential diagnosis Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 229960003444 immunosuppressant agent Drugs 0.000 description 3
- 238000002650 immunosuppressive therapy Methods 0.000 description 3
- 230000002427 irreversible effect Effects 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 230000024664 tolerance induction Effects 0.000 description 3
- 206010068051 Chimerism Diseases 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 108700039887 Essential Genes Proteins 0.000 description 2
- 208000034706 Graft dysfunction Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 2
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- 206010066901 Treatment failure Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000009093 first-line therapy Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000004957 immunoregulator effect Effects 0.000 description 2
- 229940124589 immunosuppressive drug Drugs 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000008816 organ damage Effects 0.000 description 2
- 238000002559 palpation Methods 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 201000001474 proteinuria Diseases 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- 206010048748 Graft loss Diseases 0.000 description 1
- 208000003807 Graves Disease Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- 208000033464 Reiter syndrome Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000003321 cartilage cell Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000004665 defense response Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002637 immunotoxin Effects 0.000 description 1
- 229940051026 immunotoxin Drugs 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 231100000608 immunotoxin Toxicity 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000011862 kidney biopsy Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001400 myeloablative effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Definitions
- the invention relates to nucleic acid molecules as immune markers for the detection of graft reactions, a method for the detection of graft reactions and the use of immune markers for medical prophylaxis, clinical follow-up, graft aftertreatment, clinical diagnostics and / or therapy in connection with cell and tissue - Or organ transplants, where graft reactions can be a tolerance, a rejection crisis or rejection.
- the donor organ matches the recipient tissue as closely as possible. This correspondence is ensured by the HLA system, among other things
- HLA molecules Due to the extreme genetic polymorphism, there is an extraordinarily large number of different HLA molecules. A complete agreement is only observed in identical twins, otherwise HLA molecules are unique for every human being.
- transplantation is the treatment of choice for irreversible organ failure.
- the immunoregulatory proteins can either be antibodies that cause depletion of the donor-reactive T cells, e.g. anti-CD3 immunotoxin, or antibodies and proteins that affect the activation of donor-reactive T cells, e.g. anti-CD4 antibody, anti-CD40L antibody or CTLA4-lg.
- Chimerism means the parallel presence of donor and recipient blood leukocytes using non-myeloablative procedures for donor stem cell transplantation. i So far there has been a permanent one after the transplant
- kidney transplant Case of a kidney transplant.
- biopsies are taken and histologically according to the “Bänff Score w assessed. It can be used to assess whether changes associated with acute rejection - infiltration of mononuclear cells - or chronic rejection (vasculopathy) can be detected.
- a disadvantage of the previous methods is that no decisions about. safe withdrawal of immunosuppressive therapy can be taken without risking the occurrence of rejection crises.
- Another disadvantage is that the known methods do not allow during or " after treatment, too to allow prediction of rejection crises after conventional therapies before a graft function deterioration occurs.
- the diagnostic tools and methods available so far can only be used to a limited extent to assess tolerance-inducing therapy.
- the assessment of the therapy with regard to the function of the transplant - for example of serum creatinine - comes too late, since a detectable increase in serum creatinine has already caused damage to the transplanted organ, for example the kidney.
- tolerance-inducing therapies a significant increase in serum creatinine means that the therapy has failed and that the patient will probably switch to conventional immunosuppressants with the known side effects.
- the therapy ⁇ vary before a detectable damage to the graft - for example, increases in serum creatinine - present.
- deterioration in organ function can also be caused by side effects of high-dose immunosuppressive therapy or by infections in the graft, which cannot be detected by known methods either.
- the object of the invention is therefore to provide efficient and reliable immune markers which enable reliable and rapid predictability of the risk of graft rejection or the absence thereof - as a form of tolerance - in medical prophylaxis, clinical follow-up or graft follow-up treatment.
- nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID No. 1 -
- nucleiic acid molecule which hybridizes with a nucleotide sequence according to a) under stringent conditions
- nucleic acid molecule comprising a nucleotide sequence which has sufficient homology to be functionally analogous to a nucleotide sequence according to a) or b),
- nucleic acid molecule according to a nucleotide sequence according to a) - d), which is modified by deletions, additions, substitutions, translocations, inversions and / or insertions and is functionally analogous to a nucleotide sequence according to a) to d).
- nucleic acid molecules according to the invention are associated with inflammation, in particular chronic inflammation, autoimmune diseases, lesions, general wounds and graft reactions, in particular with graft rejection or other graft dysfunction and the absence of this - as a form of graft tolerance.
- the nucleic acid molecule which has sufficient homology to be functionally analogous to a nucleotide sequence selected from the group consisting of SEQ ID No. 1-8 or its complementary nucleotide sequences is at least 40% homologous.
- the homologs show a behavior in transplant reactions which allows conclusions to be drawn about the Transplant and ' its relationship to the recipient organism.
- the nucleic acid molecule has at least 60%, preferably 70%, preferably 80%, very particularly preferably 90% homology to a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID No. 1-8 or its complementary nucleotide , wherein this nucleic acid molecule has a biological activity like the sequences shown under SEQ ID No. 1-8 or their complementary sequences.
- the nucleic acid molecule is a genomic DNA, a cDNA and / or an RNA.
- the nucleic acid molecule is particularly preferably an mRNA.
- the invention also relates to a vector which comprises a nucleic acid molecule according to the invention. Furthermore, the invention also relates to a host cell which comprises the vector in the vector according to the invention. The invention also relates to a polypeptide which is encoded by a nucleic acid molecule according to the invention.
- the invention also relates to a recognition molecule which is directed against the nucleic acid molecule, the vector, the host cell and / or the polypeptide.
- Detection substances in the sense of the invention are molecules which can interact with the structures mentioned such as nucleic acid molecules or sequences, vectors, host cells and / or polypeptides or their fragments; interact in particular so that a detection of these structures is possible.
- the recognition substances can in particular be specific nucleic acids that bind with the nucleic acid molecules mentioned, but also labeled antibodies, fluorescent markers. Carbohydrates or lipids, antisense constructs, cDNA or mRNA molecules or their fragments. It is of course also possible that the recognition substances are not proteins or nucleic acids or antibodies, but rather antibodies directed against them. In such a case, the recognition substances can in particular be secondary antibodies.
- the recognition molecules are an antibody, an antibody fragment and / or an antisense construct, in particular an RNA interference molecule.
- the autoantibodies in the sense of the invention specifically bind the polypeptides according to the invention.
- the antibodies can also be modified antibodies (eg oligomeric, reduced, oxidized and labeled antibodies).
- the term antibody used in the present description includes both intact molecules and autoantibody fragments, such as Fab, F (ab ') 2 and Fv, which can bind certain epitope determinants of the polypeptides. In these fragments, the ability of the antibody to selective binding of its antigen or receptor has been partially preserved, the fragments being defined as follows:
- Fab the fragment containing a monovalent antigen-binding fragment of an antibody molecule, can be produced by cleaving an entire antibody with the enzyme papain, an intact light
- Chain and part of a heavy chain can be obtained; .
- the Fab 'fragment of an antibody molecule can be obtained by treating an entire antibody with pepsin and then reducing it, with an intact light chain and part of the heavy chain be preserved; per antibody molecule there are two
- F (ab ') 2 the fragment of the antibody which can be obtained by treating an entire antibody with the enzyme pepsin without subsequent reduction;
- F (ab ') 2 is a dimer of two Fab' fragments held together by two disulfide bonds;
- Fv defined as a genetically modified fragment that contains the variable region of the light chain and the variable region of the heavy chain
- SCA Single chain antibody
- Polypeptide linkers are linked to a genetically fused single chain molecule.
- epitope used in the present invention means any antigenic determinant on the polypeptide.
- Epitope determinants usually consist of chemically active surface groupings of molecules such as amino acids f or sugar side chains, and usually have both specific features of the three-dimensional structure and specific charge features.
- the invention also relates to vaccines containing the nucleic acid molecule, the vector, the host cell, the Polypeptide and / or the recognition molecule optionally with a pharmaceutically acceptable carrier.
- the pharmaceutically acceptable carrier is a pharmaceutical auxiliary and / or additive known per se. These additives and carriers, which are known per se to the person skilled in the art, can also be liposomes or structures or solutions and / or buffer mixtures known in genetic engineering or other substances from the field of galenics.
- the invention also relates to a method for the detection of transplant reactions in a sample from a patient, wherein in the sample a level of at least one nucleic acid molecule selected from the group comprising:
- nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID No. 1-8 or their complementary nucleotide sequences,
- nucleic acid molecule which hybridizes with a nucleotide sequence according to a) under stringent conditions
- nucleic acid molecule comprising a nucleotide sequence which has sufficient homology to be functionally analogous to a nucleotide sequence according to a) or b),
- nucleic acid molecule which, as a result of the genetic code, has degenerated into a nucleotide sequence according to a) - c) and e) a nucleic acid molecule according to a nucleotide sequence according to a) - d), which is modified by deletions, additions, substitutions, translocations, inversions and / or insertions and is functionally analogous to a nucleotide sequence according to a) to d)
- the level is compared with a control level of a comparison sample from a healthy patient, whereby the graft reactions - which also includes the absence of the same as tolerance - are detected by a modified level in the sample compared to the control level.
- a graft reaction within the meaning of the invention is understood to mean any physiological and pathophysiological interaction of the transplant with the recipient organism, but also any isolated reaction within the graft.
- the graft reaction can therefore be a tolerance or a rejection of the graft.
- a graft reaction in the sense of the invention is also a non-pathological, i.e. a normal or healthy condition in which the graft itself can be in relation to the recipient organism.
- Invention is the designation for a biological good or a part or a small amount of one taken by sampling i, the nature of which is to be tested chemically, biologically, clinically or similarly. Sampling from the patient or from humoral or cellular components of the
- Patients are " in particular - such that the removed Subset corresponds to an average of the total amount.
- the characteristics determined by examining the sample are used to assess the amount recorded by the sample, which allows conclusions to be drawn about the total amount, for example an entire transplanted organ, such as the liver, spleen, blood or also of non-transplanted components, such as the immune system.
- the samples can be pretreated by mixing, dividing, crushing, adding enzymes or markers or otherwise.
- Various possibilities for pretreating the samples are known to the person skilled in the art. Of course, it can also be provided that the sample is taken in such a way that it does not correspond to an average of the total amount.
- a sample can be all biological and non-biological materials, such as biological tissues and fluids such as blood, lymph, urine, cerebral fluid and others.
- a transplant in the sense of the invention is an organ, tissue or a cell or a cell collection that is transplanted or to be transplanted.
- grafts can also be certain implants which consist of substances or parts which are introduced into a body for a limited period or for life in order to fulfill certain replacement functions.
- the implants can consist, for example, of inorganic matter that is coated with organic substances, such as cartilage or bone cells.
- Under graft rejection according to the invention is the induction of an immune response of the recipient to the To understand graft, wherein an immune response of the recipient is a specific protective or defense response of the body against the antigens or other structures of the graft.
- a patient is any organism that comprises a transplant, in particular a human organism.
- a healthy patient in the sense of the invention is a patient whose condition allows it to be used as a reference for the present method. Healthy in the sense of the invention does not have to mean the complete absence of diseases, transplants or pathogenic changes.
- the healthy patient represents either a single patient or an average number of patients who can serve as a comparison group such that a change in the level of the nucleic acid molecules mentioned or the structures for which they code or the recognition substances can be determined.
- a modification of the level compared to the control level means that the nucleic acid molecules or the immune markers mentioned, such as in particular the peptides or the recognition substances, have detectable changes in their concentration or activity as a protein, as a nucleic acid molecule or as antibodies compared to the control level ,
- the graft is selected from the group consisting of lungs, spleen, heart, liver, pancreas and / or of tissues, in particular islets, aortas, cartilages.
- the organs or Tissue structures can be transplanted alone or in combination.
- the level is determined as a DNA, an RNA concentration, a geexpression, a copy number of a nucleic acid, a peptide concentration, a peptide activity and / or as a concentration of isoforms.
- the person skilled in the art can advantageously choose various possibilities in order to determine the level of at least one nucleic acid molecule.
- One possibility for example, is to determine the peptide concentration which is encoded by the nucleic acid molecule using spectrographic methods.
- the level of the same only in the graft or in sections is determined either inside or outside of the body and that it in 'the surrounding tissue or K ⁇ rperenbergkeiten or in biopsy materials or liquids, such ⁇ as urine, lymph or Blood that is detected.
- the level is determined as an mRNA concentration.
- the graft reaction is a rejection crisis, a rejection reaction, a rejection course, a tolerance reaction and / or a tolerance course, which is detected by the method according to the invention.
- the course of rejection and the rejection reaction can be clinical or subclinical, for example.
- a tolerance in the sense of the invention is, for example, a long-lasting normal function of the transplanted organ without an increase in serum creatinine or proteinuria for more than 100, preferably 200, very particularly preferably 300 days.
- a reduced level means that.
- Nucleic acid molecule comprising a nucleotide sequence selected from the group comprising
- nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID No. 3 and SEQ ID No. 7 or their complementary nucleotide sequences,
- nucleic acid molecule which hybridizes with a nucleotide sequence according to a) under stringent conditions
- nucleic acid molecule comprising a nucleotide sequence which has sufficient homology to be functionally analogous to a nucleotide sequence according to a) or b), i d) a nucleic acid molecule which is a result of the genetic
- Codes to a nucleotide sequence according to a) - c) is degenerate and
- nucleic acid molecule according to a nucleotide sequence according to a) - d). which is caused by deletions, additions, Substitutions, translocations, inversions and / or
- a course of rejection can be, for example, the course of a rejection reaction with or without drug administration, whereby these drugs can be immunosuppressive substances, for example.
- the reduced level of the nucleotide sequences or their complementary nucleotide sequences or nucleic acid molecules which hybridize with these nucleotide sequences under stringent conditions or nucleotide acid molecules which have sufficient homology to be functionally analogous to the nucleotide sequences mentioned can advantageously be used to determine whether the transplant tends to unphysiological or pathological processes themselves or in relation to the recipient organism.
- an increased level of a nucleic acid molecule comprising a nucleotide sequence is selected from the group comprising
- nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID No. 1 and SEQ ID No. 2 or their complementary nucleotide sequences, b) a nucleic acid molecule which hybridizes with a nucleotide sequence according to a) under stringent conditions,
- nucleic acid molecule comprising a nucleotide sequence which has sufficient homology to be functionally analogous to a nucleotide sequence according to a) or b),
- nucleic acid molecule according to a nucleotide sequence according to a) - d), which is modified by deletions, additions, substitutions, translocations, inversions and / or insertions and is functionally analogous to a nucleotide sequence according to a) to d)
- the nucleic acid molecules mentioned include in particular the nucleic acid molecules which hybridize under stringent conditions with the nucleic acid molecules mentioned, and also those nucleic acid molecules which have sufficient homology to be functionally analogous to the nucleic acid molecules mentioned and those which degenerate as a result of the genetic code are or modified by deletions, additions, substitutions, translocations, inversions and / or insertions and are functionally related to the nucleotide sequence of the nucleic acid molecules mentioned.
- an elevated level of a nucleic acid molecule is selected from the group comprising
- nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5, SEQ ID No. 6, SEQ ID No. 7 and SEQ ID No. 8 or their complementary nucleotide sequences,
- nucleic acid molecule which hybridizes with a nucleotide sequence according to a) under stringent conditions
- nucleic acid molecule comprising a nucleotide sequence which has sufficient homology to be functionally analogous to a nucleotide sequence according to a) or b),
- nucleic acid molecule according to a nucleotide sequence according to a) - d), which by deletions, additions, substitutions, translocations, inversions and / or
- the tolerance reaction or the tolerance curve is detected.
- the invention also relates to the use of the nucleic acid molecule, the vector, the host cell, the polypeptide, the recognition molecule and / or the vaccine in medical prophylaxis, clinical course monitoring, graft aftertreatment, clinical diagnostics and / or therapy.
- the person skilled in the art can use the nucleic acid molecules or vectors according to the invention, host cells, polypeptides, recognition molecules and / or vaccines in the field of prophylaxis, follow-up, diagnosis or therapy. For example, it is possible to lower the biological structures, which are increased in their level in the event of a rejection reaction or a reaction crisis, in the form of therapy, in order to enable tolerance or conditions for a subsequent tolerance of the transplant. to support.
- RNA interference can be done, for example, by administering antisense constructs or RNA molecules that are able to generate RNA interference.
- the peptides or proteins coded by the nucleic acid molecules the t level of which may also be increased, to be functionally impaired by antibodies such that a physiological state in the transplant or between the transplant and recipient organism indicates. can be achieved or supported.
- reduced level of Increase nucleic acid molecules in the form of a therapeutic measure if a reduced level is associated with a rejection reaction or a rejection crisis.
- Various possibilities are known to the person skilled in the art to modify the level of the substances or molecules mentioned, in particular to increase them in the present case.
- An increase in a protein level is possible, for example, by adding an additional promoter to the nucleic acid encoding the corresponding protein, which may of course be present in the organism or transplant or being introduced into the transplanted organ, or by increasing the activity of the original promoter , It is also possible to increase the number of copies of the nucleic acids in the corresponding target tissue, as a result of which more nucleic acid molecules are provided and more proteins can be expressed. It is known to the person skilled in the art that such measures can be carried out not only within the therapy but also in a protocol for prophylaxis or for post-transplant treatment.
- Clinical follow-up checks or diagnostic measures can advantageously be carried out in such a way that the expression of the nucleic acid molecules or the peptides or fragments encoding them is quantified in the urine or biopsy material over certain time intervals to be determined by the person skilled in the art.
- the nucleic acid molecules and their homologues or the modified nucleic acid molecules are used for the detection of T- Cell-mediated immune processes, especially used by pathogenic T-cell-mediated immune processes.
- the nucleic acid molecules according to the invention and also their descendants, their complementary structures and the peptides that encode them can be used, for example, to detect complement reactions or other processes in which T cells have a certain meaning.
- pathogenic T-cell-mediated immune processes such as type I diabetes mellitus, rheumatoid arthritis, chronic intestinal inflammation, dermatoses and / or allergies can be detected.
- autoimmune diseases or inflammations are detected as T-cell-mediated immune processes, in particular an antiglomerular basement membrane disease, autoimmune diseases of the nervous system, a systemic lupus erythematosus, an Addison's disease, an antiphospholipid syndrome, an IgA glomerulonephritis Goodpasture syndrome, a Lambert-Eaton myasthenia syndrome, a bullous pemphigoid, a thrombocytopenic, idiopathic purpura, an autoimmune thyroiditis, a rheumatoid arthritis, an insulin-dependent diabetes mellitus, a pemphigus, an autoimmune hemiformismalemia anemia membranous glomerulonephritis, Graves disease, sympathetic ophthalmia, autoimmune polyendocrinopathies, multiple sclerosis and / or Reiter's disease.
- the T-line-mediated immune processes are physiological
- the graft reactions are a rejection crisis, a rejection reaction, a rejection course, a tolerance reaction and / or a tolerance course.
- the invention also relates to a kit comprising the nucleic acid molecule, the vector, the host cell, the polypeptide, the recognition molecule and / or the vaccine, and to the use of the kit for the detection of the graft reaction.
- the invention has several advantages. It is thus possible, in particular, to carry out a permanent check of the condition of the graft after transplantations, it being possible to obtain the nucleic acid molecules or peptides or recognition substances according to the invention used as markers from various samples of the patient, for example urine. It is thus possible, in particular, to detect deteriorations in the function of the graft at an early stage, so to speak at the beginning of the effector chain.
- the substances according to the invention and the method according to the invention therefore make it possible to diagnose processes which are already subclinical at an early stage. Subclinical reactions therefore no longer need to be determined using control biopsies and conventional histology.
- the substances mentioned can be used as markers for monitoring transplants Detect undesirable immune reactions before organ damage and with differential diagnosis.
- Monitoring can be used, for example, as a follow-up in multiple immunosuppressive regimens, with good functions being able to discontinue one or more of the immunosuppressive components, with the occurrence of accelerated rejection processes being recognized at an early stage.
- the procedure can also be optimized individually from patient to patient. It is also advantageously possible with the markers to transfer tolerance-induced protocols and tolerance-inducing therapies to humans, since after the tolerance induction therapy has been discontinued, treatment failures can be identified in good time in order to prevent irreversible damage to the transplant.
- the substances according to the invention, the method according to the invention and the uses provide exact analytical methods in order to assess the induction, the success and the maintenance of a tolerance.
- the breakdown of the tolerance for example due to the presence of an infection, can also be predicted. It is therefore possible to make decisions about safely stopping immunosuppressive therapy without advantageously risking the occurrence of reaction crises.
- An important application of the nucleic acid according to the invention of the method according to the invention is therefore the prediction of reaction crises during or after the treatment, even after conventional therapies, before a deterioration in the function of the graft occurs.
- conventional immunosuppression is also improved by the nucleic acid molecules according to the invention and the method according to the invention with regard to the early detection of clinical and subclinical acute rejection crises and the beginning of chronic reaction processes.
- the invention makes it possible to vary the therapy before there is demonstrable damage to the graft. It is also possible to use the nucleic acid molecules according to the invention and the proteins or protein fragments encoded by them for the screening of medicaments which can be used in the diagnosis and therapy of transplant reactions.
- nucleic acid molecules according to the invention can be found in
- Kidney transplants induced in the Control antibodies from treated recipient animals are rejected between days 5 and 9.
- the tolerance is characterized by long-lasting normal kidney function without increasing serum creatinine or proteinuria for more than 300 days.
- the infiltration of donor-reactive T cells is only 50% reduced, but there is no destruction of the transplanted organ.
- the mononuclear cells that had migrated into the transplant were isolated from recipient animals treated with control antibodies or RIB / 2 by collagenase digestion and Ficoll gradient on day 5 after the transplantation, and their mRNA expression was compared using the “PCR-Select” method For the isolation of cDNA fragments which are increasingly expressed in transplants of rejecting recipient animals: 2A5 and 2AI5 (corresponds to SEQ ID No. 1 and 2).
- Recipient animals is increased: 1A50, 3A29, T4, T5, T8 and T10
- Fig. 1 shows the cDNA sequence sections of the fragments mentioned.
- Oligonucleotide sequences for carrying out a real-time RT-PCR were also derived from the sequence segments shown here. With the help of these oligonucleotide sequences, a relative quantification of the expression of the corresponding mRNAs in relation to the “house keeping gene” ⁇ -actin in rat cells is possible Mouse sequences Oligonucleotide sequences for the relative quantification of the corresponding mRNAs in relation to the “house keeping gene HPRT” have been established in mouse cells.
- Fig. 2 shows the results of the expression analysis for fragments 1A50, 3A29, T4, T5, T8 and T10 in the kidney transplant model.
- the mRNA expression of the fragments in the graft for control antibody-treated recipient animals (Co) is shown on day 0 (naive kidneys), 2 and 5 after the transplantation, and the expression for RIB5 / 2-treated tolerance-developing recipient animals (RIB5 / 2) shown on day 0, 2, 5, 10, 14 and 300 after the transplant. All cDNA fragments are strongly expressed in permanently accepted grafts, whereas their expression in grafts takes control antibodies treated. ' Receiving animals drastically decreased at the time of rejection.
- Fig. 3 shows the expression of fragments 1A50 and T8 in the transplanted organ.
- the mRNA expression in grafts of pretreated tolerance-developing recipient animals (DST + YTS177) was analyzed on day 0
- cDNA fragments 2A5 and 2A15 were examined in the kidney transplant model (Fig. 5) and in the heart transplant model (Fig. 6). The expression of these cDNA fragments in the graft of rejecting recipient animals is shown in each case. Both models upregulate mRNA expression shortly before rejection. With the help of the identification and quantification of such gene markers, the expression of which in the graft, in graft fluids (urine, lavage) or peripheral blood either correlated with long-lasting good graft function or the occurrence of rejections, an assessment of the tolerance-inducing therapy would be better possible.
- the expression of 2A5 and 2A15 can be used in the biopsy to assess acute subclinical rejection crises and early chronic rejections.
- a strong, long-lasting expression would be associated with a rejection of the organ. This depends only to a limited extent on the extent of the infiltration of mononuclear cells into the transplant, since in anti-CD4 treated tolerance-developing recipient animals, the infiltration of the mononuclear cells is reduced by only 50% in the kidney transplantation model. This would significantly improve the evaluation of a biopsy, since not only the infiltration into the organ is used as a criterion for acute rejection, but also qualitative changes in the infiltrating cells.
- Expression of T4, T5, T10, 3A29, T8 and 1A50 in the biopsy can e.g. be used to assess the success of therapy. This would enable a decision to be taken to safely end tolerance-inducing therapy.
- the expression of 2A5 and 2A15 in the biopsy can be used to assess acute clinical and subclinical rejection crises and early chronic rejections. Strong, long-term expression is associated with immunological rejection of the organ. This depends only to a limited extent on the extent of the infiltration of mononuclear cells into the graft, since in anti-CD4 treated tolerance-developing recipient animals, the infiltration of the mononuclear cells is reduced by only 50% in the kidney transplant model. This significantly improves the evaluation of a biopsy, since not only the infiltration into the organ is used as a criterion for acute rejection, but also the qualitative change in the infiltrating cells.
- T4, T5, T10, 3A29, T8 and 1A50 in the biopsy is used to assess the success of the therapy.
- the sharp drop in expression of 1A50 and T8 in the periphery in rejecting recipient animals more than 2 days before the rejection enables a non-invasive diagnosis in the blood or other body fluids, such as in the urine, of the patient before organ deterioration, such as the increase in serum creatinine, can be demonstrated.
- the following diagnostic model is therefore successful after the transplant: - 1. Detection of 1A50 and " T8 in the patient's blood or other body fluids (eg urine) daily shortly after the operation and weekly / monthly in the further course in order to predict a rejection crisis and thus failure of the therapy or to detect a suppression in the case of withdrawal attempts .
- T4, T5, T8, T10, 1A50 _ and 3A29 in control biopsies or transplant-relevant body fluids to assess the success of the tolerance-inducing or conventional therapy, in particular to enable the therapy to be safely discontinued / reduced.
- TIZ transplant-infiltrating cells
- the first patient data thus confirm that the genes can also be detected in the human system and that their regulation is very similar to that in the animal models.
- Nr. 1A50 (x10- 1) 2A15 (x10 "1) 2A5 (x10" 1)
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10238922 | 2002-08-22 | ||
DE10238922A DE10238922A1 (de) | 2002-08-22 | 2002-08-22 | Immunmarker zur Diagnostik und Therapie im Zusammenhang mit Transplantat-Reaktionen |
PCT/EP2003/009355 WO2004018504A2 (de) | 2002-08-22 | 2003-08-22 | Immunmarker zur diagnostik und therapie im zusammenhang mit transplantat-reaktionen |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1532272A2 true EP1532272A2 (de) | 2005-05-25 |
Family
ID=31197348
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP03750429A Withdrawn EP1532272A2 (de) | 2002-08-22 | 2003-08-22 | Immunmarker zur diagnostik und therapie im zusammenhang mit transplantat-reaktionen |
Country Status (5)
Country | Link |
---|---|
US (1) | US20080044403A1 (de) |
EP (1) | EP1532272A2 (de) |
AU (1) | AU2003270097A1 (de) |
DE (1) | DE10238922A1 (de) |
WO (1) | WO2004018504A2 (de) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011006119A2 (en) | 2009-07-09 | 2011-01-13 | The Scripps Research Institute | Gene expression profiles associated with chronic allograft nephropathy |
CA2949959A1 (en) * | 2014-05-22 | 2015-11-26 | Northwestern University | Gene expression profiles associated with sub-clinical kidney transplant rejection |
US10443100B2 (en) | 2014-05-22 | 2019-10-15 | The Scripps Research Institute | Gene expression profiles associated with sub-clinical kidney transplant rejection |
EP3825416A3 (de) * | 2014-05-22 | 2021-09-15 | The Scripps Research Institute | Mit subklinischer nierentransplantatabstossung assoziierte genexpressionsprofile |
US11104951B2 (en) | 2014-05-22 | 2021-08-31 | The Scripps Research Institute | Molecular signatures for distinguishing liver transplant rejections or injuries |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5474796A (en) * | 1991-09-04 | 1995-12-12 | Protogene Laboratories, Inc. | Method and apparatus for conducting an array of chemical reactions on a support surface |
US7625697B2 (en) * | 1994-06-17 | 2009-12-01 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for constructing subarrays and subarrays made thereby |
US20030104371A1 (en) * | 1997-09-24 | 2003-06-05 | Strom Terry B. | Methods of evaluating transplant rejection |
JP2002530077A (ja) * | 1998-11-18 | 2002-09-17 | インサイト・ファーマスーティカルズ・インコーポレイテッド | 炎症関連遺伝子 |
-
2002
- 2002-08-22 DE DE10238922A patent/DE10238922A1/de not_active Withdrawn
-
2003
- 2003-08-22 US US10/525,180 patent/US20080044403A1/en not_active Abandoned
- 2003-08-22 WO PCT/EP2003/009355 patent/WO2004018504A2/de active Application Filing
- 2003-08-22 EP EP03750429A patent/EP1532272A2/de not_active Withdrawn
- 2003-08-22 AU AU2003270097A patent/AU2003270097A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
See references of WO2004018504A2 * |
Also Published As
Publication number | Publication date |
---|---|
WO2004018504A2 (de) | 2004-03-04 |
DE10238922A1 (de) | 2004-03-04 |
AU2003270097A8 (en) | 2004-03-11 |
WO2004018504A3 (de) | 2004-10-14 |
AU2003270097A1 (en) | 2004-03-11 |
US20080044403A1 (en) | 2008-02-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69737969T2 (de) | Dns-impfung zur einleitung einer suppressiven t-zell-antwort | |
Nashold et al. | 1, 25-dihydroxyvitamin D3 treatment decreases macrophage accumulation in the CNS of mice with experimental autoimmune encephalomyelitis | |
CN110693917B (zh) | Akkermansia Muciniphila在制备抗抑郁药物或者保健品中的应用 | |
DE3854351T2 (de) | Methode zur verminderung von gewebsschäden an einer entzündeten stelle durch verwendung von monoklonalen antikörpern. | |
DE69133393T2 (de) | Verfahren zur diagnose und behandlung von diabetes | |
DE69734141T2 (de) | PROTEIN, DAS FÜR MENSCHLICHE Th2-ZELLEN SPEZIFISCH IST, DAFÜR KODIERENDES GEN UND KORRESPONDIERENDE TRANSFORMANTE, REKOMBINANTER VEKTOR UND MONOKLONALER ANTKÖRPER | |
DE69122761T2 (de) | Verfahren und komposition zum frühnachweiss und behandlung insulinabhängiger diabetes | |
WO2006024367A2 (de) | Verwendung von blockern der nkg2d-rezeptor-/nkg2d-liganden-interaktion bei autoimmunerkrankungen | |
EP1532272A2 (de) | Immunmarker zur diagnostik und therapie im zusammenhang mit transplantat-reaktionen | |
DE69505376T2 (de) | Alpha b crystallin zur verwendung in diagnose und therapie von autoimmunkrankheiten, besonders multipler skerose | |
WO2004027428A1 (de) | Verfahren zum nachweis und zur isolierung von t-lymphozyten, die ein definiertes antigen erkennen | |
DE69635161T2 (de) | Rekombinante hetero-multimerische proteine von dem alpha-beta c4 bp typ | |
DE69233685T2 (de) | Klonierte Glutaminsäure-Decarboxylase | |
EP3714067A1 (de) | Verwendung des adipoq genexpressionslevels zur einordnung eines probanden in risikogruppen bei der prognose oder diagnose einer diabetes mellitus typ ii erkrankung | |
WO2002004664A9 (de) | Aus tumorzellen isolierbare gene mit kodierenden mononucleotid- oder dinucleotid-mikrosatelliten | |
EP1915904B1 (de) | Verfahren zur behandlung von mäusen mit menschlichen hepatozyten | |
DE69528817T2 (de) | Peptide und dessen verwendungen gegen psoriasis | |
DE60127442T2 (de) | Verfahren der pibf-konzentrationsbestimmung zur diagnose eines tumors in einem patienten | |
DE60020580T2 (de) | Zusammensetzungen zur behandlung von autoimmunkrankheiten, die mittel, welche icam-1/lfa-1 interaktionen inhibieren und mittel, welche cd40-cd40-ligande interaktionen inhibieren, enthalten | |
Rotterman et al. | Modulation of central synapse remodeling after remote peripheral injuries by the CCL2-CCR2 axis and microglia | |
DE10006887A1 (de) | Verbindungen, die die Aktivität oder die Konzentration des Regulatorproteins RS1 verändern | |
DE10213762A1 (de) | Neues costimulierendes Molekül und dessen Verwendung | |
EP0889053B1 (de) | BK-RiV-Präparate zur Behandlung von proliferativen Zellerkrangungen | |
EP1999473A1 (de) | Verfahren zur bestimmung der therapeutischen wirksamkeit von substanzen | |
DE202020005821U1 (de) | Vorrichtungen und Systeme zur Entfernung von Bestandteilen aus biologischen Flüssigkeiten |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20050316 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK |
|
DAX | Request for extension of the european patent (deleted) | ||
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: VOLK, HANS-DIETER Inventor name: WOOD, KATHRY, PROF. Inventor name: LEHMANN, MANFRED Inventor name: SAWITZKI, BIRGIT |
|
17Q | First examination report despatched |
Effective date: 20070426 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: SAWITZKI, BIRGIT Owner name: VOLK, HANS-DIETER |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20160602 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20161013 |